Dr. Thomas Nevill, MD, FRCPC

Dr. Nevill was born in London, Ontario and received his MD from the University of Toronto in 1983. He did his Internal Medicine and Hematology training at Dalhousie University in Halifax, Nova Scotia before completing a Leukemia/BMT Fellowship in Vancouver. He became the Director of the first BMT Program in Atlantic Canada in 1991 before returning to the University of British Columbia in 1996, where he is a Clinical Professor in the Division of Hematology. He is on Active Staff at both the Vancouver General Hospital and the BC Cancer Agency and in 2006 assumed the role of Clinical Director of the Leukemia/BMT Program of British Columbia. He maintains a research interest in myelodysplastic syndrome, Hodgkin's lymphoma and post-transplantation complications, including graft-versus-host disease. He is the Vice President of the Canadian Hematology Society, is on the Scientific Advisory Committee of the Canadian Blood Services and has done Grant reviews for the NCIC, CIHR and the MRC (UK).

Selected representative articles include:

1. Nevill TJ, Barnett MJ, Klingemann H-G, Reece DE, Shepherd JD & Phillips GL. Regimen-related toxicity of a busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 9: 1224-1232, 1991.
2. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingemann H-G & Phillips GL. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10: 445-450, 1992.
3. Forrest DL, Nevill TJ, Horsman DE, Brockington DA, Fung HC, Toze CL, Conneally EA, Hogge DE, Sutherland HJ, Nantel SH, Shepherd JD & Barnett MJ. Bone marrow transplantation for adults with acute leukemia and 11q23 chromosomal abnormalities. Br J Haematol 103: 630-638, 1998.
4. Nevill TJ, Fung HC, Shepherd JD, Horsman DE, Nantel SH, Klingemann H-G, Forrest DL, Toze CL, Sutherland HJ, Hogge DE, Naiman SC, Le A, Brockington DA & Barnett MJ. Cytogenetic abnormalities in primary myelodsyplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92: 1910-1917, 1998.
5. Reece DE, Nevill TJ, Sayegh A, Spinelli JJ, Brockington DA, Barnett MJ, Klingemann H-G, Connors JM, Nantel SH, Shepherd JD, Sutherland HJ, Voss NJS, Fairey RN, O'Reilly SE & Phillips GL. Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease. Bone Marrow Transplant 23: 1131-1138, 1999.
6. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ, Conneally EA, Shepherd JD, Nantel SH, Hogge DE & Klingemann H-G. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 9: 367-374, 2000.
7. Seftel MD, Bruyere H, Copland M, Hogge DE, Nantel SH, Shepherd JD, Lavoie JC, Le A, Sutherland HJ, Toze CL & Nevill TJ. Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22). Eur J Haematol 69:193-199, 2002.
8. Metayer C, Curtis RE, Vose J, Sobocinski KA, Horowitz MM, Bhatia S, Fay JW, Freytes CO, Goldstein SC, Herzig RH, Keating A, Miller CB, Nevill TJ, Pecora AL. Rizzo JD, Williams SF, Li CY, Travis LB & Weisdorf DJ. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101:2015-2023, 2003.

Back to Executive Commitee